Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Overview of attention for article published in JAMA Oncology, August 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 59 X users

Citations

dimensions_citation: 122 Dimensions

Readers on

mendeley: 75 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 122 publications that cite this research output.

122

The most recent citing publications are shown below. View all 122 publications that cite this research output on Dimensions.

Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.

Article in Acta Oncologica (May 2024)

Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution

Article in Cell Death & Disease (March 2024)

Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors

Article in Surgical Oncology Clinics of North America (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.